DDInter458 DDInter1659
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming. However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation for the treatment of various types of tumours in Phase II trials. Currently, the novel MEK 1 / 2 inhibitor, selumetinib, is approved solely for the treatment of Neurofibromatosis type 1 (NF-1) in a limited age group. NF-1 is considered rare, with an estimated incidence of 1/3000 individuals. It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications, including the development of multiple tumours in the nervous system.[A193533,A193608] Some patients with this disorder develop plexiform neurofibromas (PN); however, this is considered relatively uncommon compared to other variants of NF-1. Luckily, the use of selumetinib in patients with NF-1 have shown efficacy in shrinking associated tumours and is linked to other positive clinical outcomes. Selumetinib was approved by the FDA on April 10, 2020. It was later approved by Health Canada on August 23, 2022.
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Argatroban
Argatroban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Selumetinib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Haemorrhage
Haemorrhage {u} (Side Effect) is caused by {v} (Compound) Argatroban
Argatroban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Selumetinib
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Fluconazole
Fluconazole {u} may lead to a major life threatening interaction when taken with {v} Selumetinib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Renal impairment
Renal impairment {u} (Side Effect) is caused by {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Selumetinib
Cyclosporine {u} (Compound) downregulates {v} (Gene) CCNB2
CCNB2 {u} (Gene) is upregulated by {v} (Compound) Lapatinib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Selumetinib
Cyclosporine {u} (Compound) upregulates {v} (Gene) KLHDC2
KLHDC2 {u} (Gene) is upregulated by {v} (Compound) Lapatinib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Selumetinib
Cyclosporine {u} (Compound) downregulates {v} (Gene) CCNB2
CCNB2 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Selumetinib
Cyclosporine {u} (Compound) downregulates {v} (Gene) POLE2
POLE2 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may lead to a major life threatening interaction when taken with {v} Selumetinib
Cyclosporine {u} (Compound) upregulates {v} (Gene) KLHDC2
KLHDC2 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may lead to a major life threatening interaction when taken with {v} Selumetinib
Cyclosporine {u} (Compound) downregulates {v} (Gene) POLE2
POLE2 {u} (Gene) is upregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Selumetinib
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Argatroban (Compound) and Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Cyclosporine (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Argatroban (Compound) and Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Cyclosporine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Fluconazole (Compound) and Fluconazole may lead to a major life threatening interaction when taken with Selumetinib
Cyclosporine (Compound) causes Renal impairment (Side Effect) and Renal impairment (Side Effect) is caused by Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Selumetinib
Cyclosporine (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is upregulated by Lapatinib (Compound) and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Cyclosporine (Compound) upregulates KLHDC2 (Gene) and KLHDC2 (Gene) is upregulated by Lapatinib (Compound) and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Cyclosporine (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Cyclosporine (Compound) downregulates POLE2 (Gene) and POLE2 (Gene) is downregulated by Dabrafenib (Compound) and Dabrafenib may lead to a major life threatening interaction when taken with Selumetinib
Cyclosporine (Compound) upregulates KLHDC2 (Gene) and KLHDC2 (Gene) is upregulated by Dabrafenib (Compound) and Dabrafenib may lead to a major life threatening interaction when taken with Selumetinib
Cyclosporine (Compound) downregulates POLE2 (Gene) and POLE2 (Gene) is upregulated by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Selumetinib